Gilead Sciences Inc.
Gilead Sciences Appoints Ted W. Love, M.D., to Board of Directors
Summary
Gilead Sciences, Inc. announced on February 1, 2024, the appointment of Ted W. Love, M.D., to its Board of Directors, effective immediately. Dr. Love, a distinguished executive with extensive experience in the biopharmaceutical industry, will also serve on the Audit Committee post the 2024 Annual Meeting, subject to re-election. The appointment is part of the Board's effort to enhance its expertise and commitment to access and inclusion.
Profitelligence Alerts
Get alerts for GILD
Be first to know when Gilead Sciences Inc. files with the SEC.
Filing Categories
Exhibits (1)
Advertisement
About Gilead Sciences Inc.
Gilead Sciences Inc. is a biopharmaceutical company that focuses on researching, developing, and commercializing innovative medicines in areas of unmet medical need. It is globally recognized for its distinguished work, particularly in the treatment of HIV, liver diseases such as hepatitis B and C, and various forms of cancer. The company's portfolio includes groundbreaking antiviral therapies and a robust pipeline of investigational drugs. Headquartered in Foster City, California, Gilead Sciences Inc. significantly contributes to the healthcare sector by extending the lives of patients with serious illnesses worldwide. Through strategic partnerships and continuous innovation, Gilead remains at the forefront of modern medicine, enhancing its role in the global pharmaceutical market.
Official SEC Documents
Advertisement